Profitability Metrics

Gross Margin
33.95%
Operating Margin
17.60%
Net Margin
10.96%

Efficiency Metrics

Revenue per Expense Ratio
1.21
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
31.09%
Income Tax Rate
10.79%
EPS
6.7700000000

Balance Sheet Analysis

Current Ratio
0.60
Cash Ratio
0.00
Working Capital
$-2.34B
Debt to Equity
1.90
Debt to Assets
46.86%
Equity Ratio
24.69%

Cash Flow Analysis

Operating Cash Flow Ratio
25.26%
Free Cash Flow Ratio
-5.60%
CapEx to Revenue
30.87%
Dividends Paid
$752.00M
Stock Buybacks
No buybacks
Total Shareholder Returns
$752.00M
Cash Position Change
18.60%

Key Takeaways (2023 FY)

  • Revenue declined by 33.716455169544%, indicating potential market challenges
  • Maintained positive net income growth despite revenue changes
  • Increased dividend payments by 3.92%

Detailed Growth Metrics

Core Performance

Revenue
-33.72%
Net Income
28.99%
EPS
21.98%
Operating Income
28.32%

Operational Efficiency

R&D Expenses
0.00%
SG&A Expenses
800.00%
Operating Cash Flow
62.87%
Free Cash Flow
49.04%

Balance Sheet Health

Assets
4.85%
Debt
8.99%
Book Value per Share
0.61%
Inventory
11.89%

Shareholder Returns

Dividends per Share
3.92%
Shares Outstanding
5.64%

Long Term Trends

3Y Revenue/Share
-1.94%
5Y Revenue/Share
-21.21%
3Y Dividend/Share
-7.30%
5Y Dividend/Share
6.57%